Antimicrobial resistance (AMR) occurs as bacteria evolve and adapt to develop defence mechanisms to survive antibiotic treatment, rendering existing drugs ineffective at fighting AMR infections. AMR is a serious and growing threat, now killing over 700,000 people per year and predicted to rise to >10 million people by 2050 (more than cancer). AMR is set to cost the global economy $100 trillion, through healthcare, loss and R&D. Bacteria are continuing to evolve resistance to all existing antibiotics, calling out for an urgent solution to address this serious global challenge.
Pathogenic microbes can cause life threatening disease, which in the absence of effective treatments could result in the next pandemic. Mycobacterium tuberculosis is the causative agent of TB, which alone killed 1/4 of the adult population of Europe in the 19th Century (pre-antibiotic era). Pseudomonas aeruginosa commonly infects Cystic Fibrosis patients, where it often develops resistance to antibiotics, with lethal results for these patients.
In 1928, Sir Alexander Fleming discovered the first antibiotic (Penicillin). Since then, several classes of antimicrobials have been developed, though no new class of antibiotic has been discovered in over 30 years.
Medusa Pharmaceuticals presents a novel and powerful solution to reinvigorate existing antibiotics, restoring their power to fight AMR. This approach is based on a serendipitous discovery with global implications.